Stock data
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR) reported revenue of US$40.37M and net income of -US$119.72M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$40.37M | — | -US$131.84M | -US$119.72M | — |
| 2024 | US$80.00M | — | -US$83.29M | -US$65.00M | — |
| 2023 | US$250.01M | — | US$122.01M | US$132.33M | — |
| 2022 | US$40.91M | — | -US$50.84M | -US$46.41M | — |
| 2021 | US$37.41M | — | -US$73.62M | -US$71.20M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$3.17M | -US$24.47M | — |
| 2026-03-31 | US$2.59M | -US$27.94M | — |
| 2025-12-31 | US$15.34M | -US$27.43M | — |
| 2025-09-30 | US$13.37M | -US$27.89M | — |
| 2025-06-30 | US$5.20M | -US$33.38M | — |
| 2025-03-31 | US$6.47M | -US$31.02M | — |
| 2024-12-31 | US$6.28M | -US$34.49M | — |
| 2024-09-30 | US$24.63M | -US$9.04M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.